BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeiGene, a global oncology company, has made significant strides in the treatment of chronic lymphocytic leukemia (CLL) with its hematology franchise, led by the best-in-class Bruton's tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib). At the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego from December 7-10, 2024, BeiGene presented new data from its hematology franchise, including BRUKINSA and novel pipeline assets, further solidifying its leadership in the CLL landscape.

The 5-year follow-up data from the Phase 3 SEQUOIA study, presented at ASH 2024, demonstrated the superior long-term efficacy and safety of BRUKINSA compared to other BTK inhibitors. With a 71% reduction in the risk of progression or death, BRUKINSA outperformed ibrutinib and acalabrutinib, which showed 5-year progression-free survival rates of 63% and 58%, respectively. Additionally, BRUKINSA's safety profile remained consistent, with no new safety signals identified, further cementing its position as a best-in-class treatment for CLL.

The SEQUOIA study's findings have significant implications for the future of CLL treatment and patient outcomes. The drug's durability and efficacy, as shown by the 71% risk reduction, highlight BRUKINSA's potential to improve patient outcomes by delaying disease progression and potentially extending survival. Moreover, the consistent safety profile indicates that BRUKINSA is suitable for long-term use, making it an attractive option for both patients and healthcare providers.

One of the key aspects of BeiGene's pipeline is the fixed-duration combination therapy involving sonrotoclax and BRUKINSA. This oral-only combination offers potential benefits in patient compliance and quality of life. At a median follow-up of 19.4 months, the combination demonstrated a 99% overall response rate and a best uMRD rate of 92%, with generally good tolerability. This fixed-duration, oral-only combination could provide a more manageable treatment experience for patients, potentially improving adherence and reducing the burden of continuous therapy.

An oral-only combination therapy for CLL patients, such as the fixed-duration regimen of sonrotoclax and BRUKINSA, offers potential cost savings and accessibility benefits. By eliminating the need for intravenous infusions and hospital visits, this approach reduces healthcare resource utilization and associated costs. Additionally, oral therapies allow for improved patient convenience and adherence, potentially leading to better clinical outcomes and reduced overall treatment costs.

In conclusion, BeiGene's advancements in the CLL landscape, as demonstrated by the new data presented at ASH 2024, further solidify its leadership in the hematology franchise. The superior long-term efficacy and safety of BRUKINSA, along with the potential benefits of the fixed-duration combination therapy, position BeiGene as a key player in the CLL treatment arena. As the company continues to innovate and develop novel pipeline assets, it remains well-positioned to improve patient outcomes and shape the future of CLL treatment.